EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Elizabeth Sokol iD, Arlene Naranjo iD, Lulu Chen, Rajen Mody iD, Steven G DuBois iD, Rochelle Bagatell, Navin Pinto

Pediatric Blood & Cancer · 2026-09 · 73 (9)

DOI: 10.1002/1545-5017.70504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 23.07.2026. Verfasst von Elizabeth Sokol und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwest…. Hauptthemen laut MEDLINE: Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, United Therapeutics Corporation, National Cancer Institute of the National Institutes of Health under award numbers U10CA180886, U10CA180899, U10CA098543, and U10CA098413 to the Children's Onc….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse. Prospective data regarding long‐term outcomes following this therapy have not been reported. Five‐year progression‐free survival (PFS) and overall survival (OS) for patients treated with chemoimmunotherapy were 22.6% ± 6.6% and 54.7% ± 7.7%, respectively. Patients with early disease progression following treatment on ANBL1221 tended to have been diagnosed with high‐risk neuroblastoma at a younger age than those without early disease progression. A subset of chemoimmunotherapy‐treated patients survived ≥2 years, but most all received additional therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalImmunotherapyHumansIrinotecanChild, PreschoolAntibodies, MonoclonalInfantFemaleChildTemozolomideMaleSurvival RateDrug Resistance, NeoplasmFollow-Up Studies

Stichwörter der Autor:innen

chemoimmunotherapylong‐term outcomesrelapsed/refractory neuroblastoma

Substanzen

IrinotecanAntibodies, MonoclonalTemozolomidedinutuximab

Autor:innen und Institutionen

  • Division of Pediatric Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida, USA.
  • C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Pediatrics, Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.

ORCID-Profile: Elizabeth Sokol, Arlene Naranjo, Rajen Mody, Steven G DuBois

Förderung

  • NCI NIH HHS
  • United Therapeutics Corporation
  • National Cancer Institute of the National Institutes of Health under award numbers U10CA180886, U10CA180899, U10CA098543, and U10CA098413 to the Children's Onc…

Zitieren

APA

Sokol, E., Naranjo, A., Chen, L., Mody, R., DuBois, S. G., Bagatell, R., & Pinto, N. (2026). Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatric Blood & Cancer, 73(9). https://doi.org/10.1002/1545-5017.70504

Vancouver

Sokol E, Naranjo A, Chen L, Mody R, DuBois SG, Bagatell R, et al. Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatric Blood & Cancer. 2026;73(9). doi:10.1002/1545-5017.70504

BibTeX
@article{Sokol2026,
  author = {Sokol, Elizabeth and Naranjo, Arlene and Chen, Lulu and Mody, Rajen and DuBois, Steven G and Bagatell, Rochelle and Pinto, Navin},
  title = {Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {9},
  doi = {10.1002/1545-5017.70504}
}
Kostenlos starten →